CPMV
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. It offers MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in mice, dogs, and humans. The company was founded in 2020 and is based in Novato, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.02 | $0 | -$3,550 |
| 2025 Q4 | -0.02 | $0 | -$276,565 |
| 2025 Q3 | -0.02 | $0 | $145,621 |
| 2025 Q2 | -0.02 | $0 | -$32,347 |
| 2025 Q1 | -0.03 | $0 | -$29,089 |
| 2024 Q4 | -0.02 | $0 | -$20,717 |
| 2023 Q3 | -0.05 | $0 | -$110,072 |
| 2023 Q2 | 0.00 | $0 | -$118,807 |